Individualized cancer vaccines and antibody-drug conjugates will be among the dominant biotech innovations in cancer next ...

Jim Lacamp, Morgan Stanley Wealth Management senior vice president, joins CNBC's 'Money Movers' to discuss his outlook on the ...

The stock's fall snapped a four-day winning streak.

In recent years, there has been a noted increase in the rates of chronic disease, as well as a growth in the number of ...

Morgan Stanley maintains a solid balance sheet, with assets reaching $1.26t and shareholder equity rising to $103.6b. Read ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Read here for the advantages and risks of Morgan Stanley's Series A preferred shares vs. CoCos, with insights on market ...

Morgan Stanley’s stock (NYSE: MS) gained over 30% year-to-date. This compares to rival Goldman Sachs stock, which has seen its stock gain over 40% year-to-date. So what are some of the trends ...

Nvidia’s (NASDAQ:NVDA) seemingly never-ending surge has been more muted in recent times. While sentiment has far from soured ...

Morgan Stanley has teamed up with cross-border money transmitter Wise to settle foreign-exchange payments for the investment ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Morgan Stanley. Looking at options history for Morgan Stanley MS we detected 18 trades. If we consider the specifics of ...

A portfolio of Brightview Senior Living communities spanning four markets, including Philadelphia, has sold to one of America ...